Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin rosuvastatin11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.
- 1 March 2001
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 87 (5), 33-36
- https://doi.org/10.1016/s0002-9149(01)01455-2
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Should intensive cholesterol lowering play a role in the management of acute coronary syndromes?The American Journal of Cardiology, 2000
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Prevention of coronary heart disease in clinical practice Recommendations of the Second Joint Task Force of European and other Societies on Coronary PreventionEuropean Heart Journal, 1998
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJAMA, 1998
- Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S)Circulation, 1998
- Cholesterol Reduction Yields Clinical BenefitCirculation, 1998
- What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease?Atherosclerosis, 1997
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)JAMA, 1993